Innovation

A globally first-in-class immunomodulatory drug, classified as a new Category 1 drug.

Indications

Autoimmune diseases, metabolic syndrome, graft-versus-host disease (GvHD), viral pneumonia (including COVID-19), etc.

Research and Development Timeline

2009  Professor Liu Yang's team first discovered the regulatory role of the CD24-Siglec signaling pathway in inflammation responses triggered by tissue damage.

2021  Based on the inflammatory response regulation mechanism of the CD24-Siglec pathway, OncoC4 (AcroImmune) designed a novel Siglec agonist, A1-071.

2022  The product entered the clinical trial phase.